Charles Hasbrook, MD
Family Practice · Indianapolis, INNPI 1760580526
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Novo Nordisk at 45.2% of the total. Among family practice clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$446
- GSK$180
- AbbVie$116
- Astellas Pharma US Inc$58
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$46
- Boehringer Ingelheim$41
- plus $99 from 5 others
What the payments were for
- Food & beverage$987100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $446 |
| GSK | 9 | $180 |
| AbbVie | 7 | $116 |
| Astellas Pharma US Inc | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Boehringer Ingelheim | 3 | $41 |
| Arbor Pharmaceuticals, Inc. | 3 | $41 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Novartis | 1 | $12 |
| Pfizer | 1 | $12 |
How this compares
$987 in reported general payments places this provider in the 95th percentile of 188 family practice providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 175 | $200,725 |
| EliquisApixaban | 106 | $81,844 |
| JardianceEmpagliflozin | 47 | $76,499 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $21,490 |
| RybelsusSemaglutide | 16 | $19,213 |
| MyrbetriqMirabegron | 21 | $16,229 |
| TrulicityDulaglutide | 15 | $15,011 |
| MounjaroTirzepatide | 15 | $13,558 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $9,476 |
| EntrestoSacubitril/Valsartan | 11 | $9,046 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,478 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $5,992 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $3,360 |
| Dexlansoprazole DrDexlansoprazole | 13 | $3,279 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 102 | $3,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $446 | $219,938191 claims |
| PfizerEliquis | $12 | $81,844106 claims |
| Boehringer IngelheimJardiance | $41 | $76,49947 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $180 | $30,96544 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $16,22921 claims |
| NovartisEntresto | $12 | $9,04611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 188 family practice providers in Indiana.
Other family practice in Indianapolis
- Celia MenkeIndianapolis$50
- Kimberly SmithIndianapolis$0
- Seth HunterIndianapolis$0
- Katie BuelIndianapolis$0
- Alicia AlmeidaIndianapolis$0
- Michael DayIndianapolis$0
- Sheri Ann ChengIndianapolis$0
- Aimee HeerdIndianapolis$0
- Seth RinderknechtIndianapolis$0
- Ausama IsmailIndianapolis$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.